Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.57 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.51 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26668458 | 0.94 | SLC2A1 (0.59) | SLC2A1KDM4EPKMGPR119TGFBR1 | |
| SCHEMBL30876487 | 0.93 | SLC2A1 (0.53) | SLC2A1CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL22406147 | 0.93 | SLC2A1 (0.53) | SLC2A1CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL30876501 | 0.93 | SLC2A1 (0.53) | SLC2A1CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL791915 | 0.89 | SLC2A1 (0.63) | SLC2A1CHRNB4CHRNA3KDM4EPKM | |
| SCHEMBL13160667 | 0.88 | SLC2A1 (0.55) | SLC2A1KDM4EPKMGPR119TGFBR1 | |
| SCHEMBL29576543 | 0.88 | SLC2A1 (0.55) | SLC2A1KDM4EPKMGPR119CHEK2 | |
| SCHEMBL22265848 | 0.88 | SLC2A1 (0.55) | SLC2A1KDM4EPKMGPR119CHEK2 | |
| SCHEMBL864389 | 0.88 | SLC2A1 (0.55) | SLC2A1KDM4EPKMGPR119CHEK2 | |
| SCHEMBL13096956 | 0.88 | YAP1 (0.60) | SLC2A1KDM4EPKMGPR119TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3668877-B1 | INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2024-05-01 | — | — | EP | disclosed |
| CN-109641918-B | Imidazoles as inhibitors of histone demethylases | 欧洲肿瘤研究所有限责任公司 | 2021-12-21 | — | — | CN | disclosed |
| US-10980777-B2 | Indole derivatives as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2021-04-20 | — | — | US | disclosed |
| US-20200289463-A1 | INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2020-09-17 | — | — | US | disclosed |
| US-10167260-B2 | 2-aminopyridine-based selective neuronal nitric oxide synthase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2019-01-01 | — | — | US | disclosed |
| US-20170298021-A1 | 2-Aminopyridine-based Selective Neuronal Nitric Oxide Synthase Inhibitors | NORTHWESTERN UNIVERSITY (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298021-A1 | 2-Aminopyridine-based Selective Neuronal Nitric Oxide Synthase Inhibitors | NORTHWESTERN UNIVERSITY (US) | 2017-10-19 | — | — | US | disclosed |
| US-9732037-B2 | 2-aminopyridine-based selective neuronal nitric oxide synthase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732037-B2 | 2-aminopyridine-based selective neuronal nitric oxide synthase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160347713-A1 | 2-Aminopyridine-based Selective Neuronal Nitric Oxide Synthase Inhibitors | NORTHWESTERN UNIVERSITY | 2016-12-01 | — | — | US | disclosed |
| US-9416106-B2 | 2-aminopyridine-based selective neuronal nitric oxide synthase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150368201-A1 | 2-Aminopyridine-based Selective Neuronal Nitric Oxide Synthase Inhibitors | NORTHWESTERN UNIVERSITY | 2015-12-24 | — | — | US | disclosed |
| US-9120750-B2 | 2-Aminopyridine-based selective neuronal nitric oxide synthase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2015-09-01 | — | — | US | disclosed |
| WO-2014138460-A1 | 2-AMINOPYRIDINE-BASED SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS | NORTHWESTERN UNIVERSITY (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140256016-A1 | 2-Aminopyridine-based Selective Neuronal Nitric Oxide Synthase Inhibitors | NORTHWESTERN UNIVERSITY (US) | 2014-09-11 | — | — | US | disclosed |
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2194044-A1 | QUINOLONE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347713-A1 | 2-Aminopyridine-based Selective Neuronal Nitric Oxide Synthase Inhibitors | NOS2, NOS1, NOS3 | SLC2A1 2003/4885CHRNB4 23/4885CHRNA3 56/4885 |
| US-20140256016-A1 | 2-Aminopyridine-based Selective Neuronal Nitric Oxide Synthase Inhibitors | NOS2, NOS1, NOS3 | SLC2A1 2003/4885CHRNB4 23/4885CHRNA3 56/4885 |
| US-10980777-B2 | Indole derivatives as histone demethylase inhibitors | KDM1B, KDM1A, INMT | SLC2A1 2990/4885CHRNB4 1472/4885CHRNA3 699/4885 |
| US-20200289463-A1 | INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, INMT | SLC2A1 2990/4885CHRNB4 1472/4885CHRNA3 699/4885 |
| US-20150368201-A1 | 2-Aminopyridine-based Selective Neuronal Nitric Oxide Synthase Inhibitors | NOS2, NOS1, NOS3 | SLC2A1 2003/4885CHRNB4 23/4885CHRNA3 56/4885 |
| US-10167260-B2 | 2-aminopyridine-based selective neuronal nitric oxide synthase inhibitors | NOS2, NOS1, NOS3 | SLC2A1 2003/4885CHRNB4 23/4885CHRNA3 56/4885 |
| US-20170298021-A1 | 2-Aminopyridine-based Selective Neuronal Nitric Oxide Synthase Inhibitors | NOS2, NOS1, NOS3 | SLC2A1 2003/4885CHRNB4 23/4885CHRNA3 56/4885 |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | SLC2A1 385/4885CHRNB4 2379/4885CHRNA3 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.